URD

After 2 years of optimizing its online databases, Artmarket.com posts substantial Q3 2023 turnover growth: up 75%

Retrieved on: 
화요일, 11월 7, 2023
Knowledge, UI, Peter Hancock (professor), Suggestion, AMF, Fruit, RWD, Catalog, Health, History, Art market, URD, UX, Advertising, Euronext Paris, Statistics, Biography, Thierry Ehrmann, Codex, Collection, Investment, Back office, Communication, Uncertainty, Archive, COVID-19, Cryptocurrency, Video game, Industrial design, Online shopping, Auction, Book, Artprice, Art

As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.

Key Points: 
  • As a result, our turnover for the 3rd quarter of 2023 has posted a 75% increase versus the year-earlier period.
  • From early September 2023, the final online version of Artprice.com by Artmarket , World Leader in Art Market Information for 25 years, has become the Art Market benchmark in terms of customer experience and ergonomics.
  • In the long term, we can therefore expect significant turnover growth (due to higher traffic) and this has already been confirmed by our Q3 2023 figures which show a 75% turnover increase vs. Q3 2022.
  • With the new advertising revenue, Artprice by Artmarket expects to double its turnover in 2023/2024 versus the previous financial year.

Urban Renaissance Development Announces Plan to Revitalize Atlanta University Center Community with 200+ New Build-to-Rent Homes

Retrieved on: 
화요일, 10월 17, 2023
REIT, Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Urban Planning, Renaissance, Partnership, Walking, Knowledge, Doctor of Philosophy, Real estate, Mercedes-Benz Stadium, Morehouse College, AUC, MARTA, Atlanta University Center, Mills Lane, URD, Dean, Housing, Management, Construction

Urban Renaissance Development (URD) is developing 200+ build-to-rent townhomes, brownstones, flats and single-family homes aimed at breathing new life to the long-overlooked historic Atlanta University Center (AUC) district.

Key Points: 
  • Urban Renaissance Development (URD) is developing 200+ build-to-rent townhomes, brownstones, flats and single-family homes aimed at breathing new life to the long-overlooked historic Atlanta University Center (AUC) district.
  • URD is focused on developing market-rate rental homes for Atlanta’s workforce that will complement existing neighborhoods near the multi-phase project.
  • “Despite its rich heritage and significance to the black community nationwide, this area has been neglected long enough.
  • “To achieve this, we are pursuing both self-performance and partnership strategies for various phases of our project.”
    View source version on businesswire.com: https://www.businesswire.com/news/home/20231017626818/en/

Poxel Announces the Approval of a Prospectus for the Listing of New Shares on Euronext Paris

Retrieved on: 
금요일, 6월 30, 2023
Biotechnology, Pharmaceutical, Health, Exercise, NASH, IRIS, DSM-IV codes, Prospectus, URD, ORA, Euronext Paris, Fatty liver disease, AMF, Security (finance), Euronext

POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces that the Autorité des Marchés Financiers (AMF) approved today a Prospectus for the admission of new shares of the Company that have been and may further be issued upon exercise of bonds redeemable in shares (ORA) or bonds redeemable in new or existing ordinary shares (ORANE) that already been issued or that may further be issued pursuant to the financing agreements entered into with IRIS, respectively on August 5, 2022 and March 22, 2023.

Key Points: 
  • POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announces that the Autorité des Marchés Financiers (AMF) approved today a Prospectus for the admission of new shares of the Company that have been and may further be issued upon exercise of bonds redeemable in shares (ORA) or bonds redeemable in new or existing ordinary shares (ORANE) that already been issued or that may further be issued pursuant to the financing agreements entered into with IRIS, respectively on August 5, 2022 and March 22, 2023.
  • The Prospectus has been published to enable the admission on Euronext Paris of these new shares of the Company when their number will exceed 20% of the number of existing ordinary shares of the Company as from the date of the issuance of the new shares that occurred upon the first redemption of bonds redeemable in shares (ORA) on August 9, 2022.
  • The Prospectus approved by the AMF under number 23-252 consists of:
    the 2022 Universal Registration Document of the Company filed with the AMF on April 28, 2023 under number D.23-0393 (the “URD”),
    the amendment to the 2022 URD filed with the AMF on June 29, 2023 under number D.23-0393-A01,
    This press release and the information it contains do not, and will not, constitute an offer to subscribe for or sell, nor the solicitation of an offer to subscribe for or buy, any securities of the Company in any jurisdiction.
  • Copies of the Prospectus are available free of charge on the website of the Company ( www.poxelpharma.com ) and the AMF ( www.amf-france.org ) and at the registered office of the Company, 259/261 Avenue Jean Jaurès – Immeuble le Sunway – 69007 Lyon, France.

Affluent Medical : Availability of the Universal Registration Document Universal Registration Document (URD) 2022

Retrieved on: 
수요일, 4월 26, 2023
Bank statement, Pathology, XBRL, Share repurchase, URD, ESEF, Regulatory News Service, ISIN, AMF, Mortality, Aix-en-Provence, Medtech, Urinary incontinence, Medical device, Pharmaceutical industry

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • An English version of the 2022 Universal Registration Document will be made available shortly.
  • Affluent Medical develops next-generation, mini-invasive, innovative, adjustable, and biomimetic implants to restore critical physiological functions.
  • KaliosTM, the first mitral adjustable annuloplasty ring, should be the first Affluent Medical device to be marketed.

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

Retrieved on: 
화요일, 4월 25, 2023
Kepler, Medical Affairs Bureau, Society, Head, NANO, Research and development, Patient, AMF, EIB, Nanotechnology, Maintenance, Cash, Expansion, SITC, Coronavirus Scientific Advisory Board, Research, Society for Immunotherapy of Cancer, Nanobiotix, FDA, Conference, Conference call, Cancer, CMO, PFS, Administration, Annual report, Webcast, ORR, Partnership, SG, Bank statement, Clinical trial, URD, Federal Executive Boards, NBTXR3, Pharmaceutical industry, Cryptocurrency, Security (finance), Online shopping, Immunotherapy, Euronext

PARIS and CAMBRIDGE, Mass., April 24, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, provided an update on operational progress and reported financial results for the year ended December 31, 2022, and announced the filing of its universal registration document (URD) for the financial year ended December 31, 2022 with the French financial market authority (Autorité des marchés financiers or AMF), as well as of the Annual Report on Form 20-F for the financial year ended December 31, 2022 with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • Net loss: Net loss attributable to shareholders was €57.0 million, or €1.64 per share, for the twelve-month period ended December 31, 2022.
  • Cash and Cash Equivalents: As of December 31, 2022, Nanobiotix had €41.4 million in cash and cash equivalents, compared to €83.9 million as of December 31, 2021.
  • We experienced net losses of €57.0 million in 2022 and a net decrease in cash and cash equivalents of €42.5 million in 2022.
  • During the call, Laurent Levy, chief executive officer, and Bart van Rhijn, chief financial officer, will briefly review the Company’s year-end results and an update on business activities before taking questions from participants.

Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

Retrieved on: 
금요일, 3월 31, 2023
File, Saint-Herblain, Valneva SE, Corporate governance, URD, Euronext Paris, VLA, Supervision, AMF, Cryptocurrency

Saint-Herblain (France), March 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 30 2023, of its 2022 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.23-0199 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).

Key Points: 
  • Saint-Herblain (France), March 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, announced today the filing, on March 30 2023, of its 2022 Universal Registration Document (URD) with the French Financial Markets Authority (AMF) under the filing number D.23-0199 and its Form 20-F with the U.S. Securities and Exchange Commission (SEC).
  • Valneva’s 2022 Universal Registration Document includes the Company’s 2022 audited Annual Financial Report, the Management Board Report, the Supervisory Board’s report on Corporate Governance and the Group’s Corporate Social Responsibility Report.
  • These documents are available on Valneva’s website ( https://valneva.com/investors/financial-reports/ ) and will also be available on the AMF ( www.amf-france.org ) and SEC ( www.sec.gov ) websites, respectively.
  • Hard copies of these documents may be obtained from the Company, free of charge, upon request at the following address: 6 rue Alain Bombard, 44800 Saint-Herblain, France.

DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document

Retrieved on: 
목요일, 3월 2, 2023
Annual report, Form, URD, DBV Technologies, DBV, Cryptocurrency, Euronext

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) and the filing of its 2022 Universal Registration Document (“URD”) for the year ended December 31, 2022 with the French market authority, “Autorité des Marchés Financiers” (“AMF”).

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “Company”), today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission (“SEC”) and the filing of its 2022 Universal Registration Document (“URD”) for the year ended December 31, 2022 with the French market authority, “Autorité des Marchés Financiers” (“AMF”).
  • These documents can be accessed on the Investors section of the Company's website at www.dbv-technologies.com .
  • In addition, the URD is available on the AMF’s website at www.amf-france.org and the Form 10-K is available on the SEC’s website at www.sec.gov .
  • Printed copies of both documents are available, free of charge, at the Company’s headquarters and registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge, France.

Bonduelle - First Quarter FY 2022-2023 Revenue: Growth driven by price increases in the first quarter

Retrieved on: 
화요일, 11월 8, 2022
Annual general meeting, General officer, Annual, BFA, News, Contract, URD, Growth, Acquisition, Retail, Agriculture, Health insurance, Clothing, Cassegrain, Bonduelle

In Eurasia, the Bonduelle brands, and in particular Globus, are still experiencing a solid growth in both volume and value.

Key Points: 
  • In Eurasia, the Bonduelle brands, and in particular Globus, are still experiencing a solid growth in both volume and value.
  • The Universal Registration Document (URD) for the 2021-2022 financial year can be consulted on the website www.bonduelle.com.
  • will require further price increases during the financial year and will limit the growth of sales volumes.
  • The revenues in foreign currency over the given period are translated into the rate of exchange for the comparable period.

Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares

Retrieved on: 
수요일, 9월 28, 2022
Nasdaq, ADS, Note, Goldman Sachs, Commercial code, U.S. Securities and Exchange Commission, URD, Research, Prospectus, Council, Sale, Supervisory board, Company, European, Person, Code, ADSS, AMF, Attention, SEC, Conseil, Intention, VLA, Vaccine, Chikungunya, Telephone, Marketing, Guggenheim Partners, Private, Lyme disease, European Parliament, LLC, Madison Avenue, Jefferies Group, Form, American depositary receipt, Euronext Paris, Infection, Security (finance), Global, EU, Euronext

Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. are acting as joint bookrunners for the Global Offering.

Key Points: 
  • Goldman Sachs, Jefferies, Guggenheim Securities and Bryan, Garnier & Co. are acting as joint bookrunners for the Global Offering.
  • All securities to be sold in the Global Offering will be offered by the Company.
  • The offering price per ADS in U.S. dollars and the corresponding offering price per ordinary share in euros, as well as the number of ADSs and ordinary shares sold in the Global Offering, will be determined following a book building process commencing immediately.
  • Bpifrance Participations S.A., which is an existing shareholder, has indicated an interest in purchasing up to an aggregate of 5.0 million of the ordinary shares in the Global Offering at the offering price.

Vantiva: Technicolor officially becomes VANTIVA

Retrieved on: 
화요일, 9월 27, 2022
Hive Connected Home, Twitter, LinkedIn, Growth, Industry, OTCQX, TCS, Housing, Communities and Local Government Committee, URD, Goal, Solution, EMEA, Board of directors, General officer, Lead, Board, AMF, Document, Euronext Paris, Management, Video game, Technicolor

As part of the change in corporate name, VANTIVA has launched a new global website that can be found at www.vantiva.com .

Key Points: 
  • As part of the change in corporate name, VANTIVA has launched a new global website that can be found at www.vantiva.com .
  • Luis Martinez-Amago, Chief Executive Officer of VANTIVA, said: Under the VANTIVA banner, we are beginning a new exciting journey as an independent company with two market-leading divisions and a stronger financial profile to pursue our dedicated strategy and goals.
  • Following the distribution of 65% of Technicolor Creative Studios, VANTIVA is composed of two divisions - Connected Home and Vantiva Supply Chain Services (VSCS) (formerly named DVD Services) recognised as leaders in their respective markets, and holds the remaining 35% in TCS.
  • VANTIVA is committed to the highest standards of corporate social responsibility and sustainability across all aspects of their operations.